Home › NCT07693452

Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

Use of Metformin in Patients With Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

Who can join

Ages 18 and older · All sexes

Key Inclusion Criteria (complete details available in protocol):

* Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to presumed appendiceal mucinous neoplasms (AMNs) with recurrent/refractory disease s/p cytoreductive surgery(CRS)/hyperthermic intraperitoneal chemotherapy (HIPEC), unresectable disease, or without planned CRS/HIPEC
* Age ≥18 years
* ECOG performance status ≤2

Key Exclusion Criteria (complete details available in protocol):

* Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS/HIPEC
* Patients currently taking metformin for another medical indication
* Patients with a prior adverse event to administration of metformin

About the study

This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).

What is being tested

• Metformin (drug)

Sponsor: University of California, Irvine · Participants: 15 · Started: Jun 18, 2026

Contact the study team

• Chao Family Comprehensive Cancer Center University of California, Irvine · Phone: 1-877-827-8839

Official record on ClinicalTrials.gov — NCT07693452

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.